EZH2 mutations are frequent and represent an early event in follicular lymphoma. - Wikidata - wikimedia - TriplyDB

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

http://www.wikidata.org/entity/Q37272035

about

The epigenetic basis of diffuse large B-cell lymphoma Follicular lymphoma: 2014 update on diagnosis and management The role of aberrant proteolysis in lymphomagenesis EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis The European Hematology Association Roadmap for European Hematology Research: a consensus document Nature and importance of follicular lymphoma precursors.Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.EZH2 alterations in follicular lymphoma: biological and clinical correlations.Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy Polycomb genes, miRNA, and their deregulation in B-cell malignancies EZH2 as a potential target in cancer therapy.Histone methylases as novel drug targets: developing inhibitors of EZH2.Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth EZH2 is a sensitive marker of malignancy in salivary gland tumors.Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?Targeting EZH2 and PRC2 dependence as novel anticancer therapy.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission.Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.Examining the impact of gene variants on histone lysine methylation EZH2: an emerging role in melanoma biology and strategies for targeted therapy.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.Role of the ubiquitin proteasome system in hematologic malignancies.Chemotherapy-free treatment in patients with follicular lymphoma.Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing.The molecular pathogenesis of B-cell non-Hodgkin lymphoma.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Driver mutations of cancer epigenomes.Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Epigenetic dysregulation in follicular lymphoma.Catalog of genetic progression of human cancers: non-Hodgkin lymphoma.Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.

P2860

Q26852288-8C794397-3F90-4AD6-AF60-65C71F7A72F8 Q27021850-353908F5-D216-4305-811D-24B3FD5983CA Q28084404-E62049BE-E7DF-4106-A1EF-E37A88F53A84 Q28771717-1F605590-D93D-41AF-9D63-43EE19E8D7FA Q28830861-2DDC85F7-7E90-4CE9-8649-1E39B5D8D536 Q33558757-915E6224-C8C7-41EA-99F0-87E3B8337C0E Q33578875-09370234-0208-4CC5-BEF8-AF521926D21B Q33701840-2181F98B-80B5-454D-9384-2126D18C1936 Q34423830-053B5D49-FBEE-437C-A03A-2592670ADBA4 Q35103527-FDFCCFE6-B563-4D53-854B-EBFEB6F3D995 Q35222823-650D613A-9587-4AB1-BAB5-FE26DD58ACD6 Q35510392-3FDDC06F-DAF6-4E00-B7CB-699488F62A7E Q35550139-287C2D11-44FF-4B83-B039-C0E38D61A35D Q36071043-D4F8BF39-18D1-41C4-BC0C-82453B8ECBA2 Q36140942-FB9CAFC1-5B4F-417F-AD54-3158D03A81B5 Q36445523-9AEB0448-28A5-4D06-9FF0-7425A51EB9B6 Q36920426-B5CBFF3A-9F55-4C87-9220-C122FB8AA208 Q37047704-28786CDD-D3E1-44C6-B476-B83E24D98226 Q37558207-FE97D0D6-A73C-45A8-A9E2-6EADB952B009 Q37579101-E53B0376-747A-4955-9C49-140DEC382772 Q38214120-A1CEE3F0-F56A-45F6-9C76-844BAE7A0737 Q38214535-C2DBB405-632E-49DF-B817-2FD64E08A1FC Q38218836-669D3B75-19A8-4E44-9192-14140E53E309 Q38240579-CFAF69FC-A1BC-4A78-9B3F-7F90396A76CB Q38261107-BB56A569-2D8A-4AD0-8B46-677C01856318 Q38289055-36DF4476-6F26-4539-BCAB-6328CEFA7AE1 Q38317235-E9C0034C-3E05-4F8F-ABCF-D8E8D94303AD Q38385507-61A407E0-FCBE-428D-8108-03912E7FA6E6 Q38495121-76F6446F-076B-43A6-8A29-3CAC03046C6E Q38594531-C9F27680-F819-4B46-A1F4-270C11008DA2 Q38639828-ED832E05-B0FB-4A9A-B38E-54EDADDA4FE1 Q38646971-2202D36B-9AF0-4D05-9D51-B1949FAC854E Q38663689-0A4D9396-6DC8-4463-9313-5A2A87D621B6 Q38664822-C42A962A-6CF7-46F7-BA02-5A16A4F3D653 Q38677466-9E89DEC4-AF13-4F51-BE10-4C142A0441C3 Q38766227-8FBE8BCE-A1BC-418F-8749-CA3F11DAB0DF Q38801974-E5D868DB-1048-4D83-8976-2F1904F61156 Q38882112-E605CDA4-AB9F-427E-AFA1-FBE8DA77CF8F Q38906194-D16C4AA8-2EC1-420F-AA84-4C2D79DA2557 Q38961785-66000F23-45AA-44F3-B90A-601A4A3C870B

P2860

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

http://www.wikidata.org/entity/Q37272035

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

@en

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

@nl

type

label

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

@en

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

@nl

prefLabel

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

@en

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

@nl

P1433

Q37272035-1D4B069A-3362-4DF1-BE18-E6DCB67DC19F

P1476

Q37272035-90080F62-1756-49DF-9AF5-2E3663D237F6

P2093

Q37272035-0E361780-8362-4E0D-B2E0-8C6830D2B261

Q37272035-13255E75-C435-4972-A5EC-261FFDD70644

Q37272035-36E0CCFF-7AE0-4BB7-BD10-F56AB33E6B34

Q37272035-3E36902C-133A-4541-BDB8-C62417FC58FC

Q37272035-5133DC74-9A42-49A7-9425-76200E0B8B25

Q37272035-534034C3-87EE-448F-B374-80FF725A28D8

Q37272035-5E27C0BE-2B07-4B6F-8A1E-2B6DA382CB8B

Q37272035-6091A6FD-8B27-4E06-870B-2AC23926FDE6

Q37272035-664B395F-EC6B-40A3-B9F8-62908D4FD401

Q37272035-69887513-9A86-40E1-BBB2-111DFACD0E2B

P2860

Q37272035-1160B742-42A4-45CD-9C5A-74423FF1C461

Q37272035-235235F4-5B3C-44F2-9753-F262587C2707

Q37272035-3058D086-CAE0-422D-860D-665C65178DBC

Q37272035-36DB3077-DA77-4EFC-8738-A609E5B9244E

Q37272035-3A2652B9-1939-4EC6-82EC-130904389E2F

Q37272035-41448E5B-82A6-4ACC-ABAF-826BC8C35FEF

Q37272035-44418C82-522C-4875-8134-B3F88967ED6C

Q37272035-448BC8C8-C6B6-48E4-B9A3-E62F49A85F21

Q37272035-61455E37-824B-4953-B543-E34141CDD85A

Q37272035-7692257A-30B3-4C3D-A7D7-9DB9A5881411

P304

Q37272035-BC00C727-5EC8-4FB6-8A76-9B57E80ECB34

P31

Q37272035-38E1FEF6-D695-41C0-83F7-27FED799B538

P356

Q37272035-7DAD111A-AD7A-4450-80A6-F344364D4F68

P407

Q37272035-FE689994-CDB7-4D25-9950-9FADF6A8EF2D

P433

Q37272035-9E32C8AE-0F33-4C5A-9E62-80518444EC26

P478

Q37272035-25587BCC-036B-485B-A651-DE45955CA14B

P50

Q37272035-388391D7-ADCE-4E4E-AD62-8B6150EB7380

Q37272035-44B153D5-2D81-42E2-A984-95EE29548EBC

Q37272035-4990189F-216F-40F0-A814-9786EDE1FA0B

Q37272035-66C621E3-55C9-4CC3-86D9-8A891F591E01

Q37272035-6B10B3EE-8804-4D82-96F9-5737D5C4196C

Q37272035-6D531437-AABD-4BD8-B98B-7F92764B5F39

Q37272035-6F826A69-7A51-44AD-9473-262F60828799

Q37272035-8808FC2B-CBDA-4985-991B-A7994C1BE4A0

Q37272035-9E1A1D96-68DF-4F60-98AB-5E101101F65C

Q37272035-D6556C55-3AF5-47AB-B869-BC2DBFC4F28A

P577

Q37272035-B79E358D-B27F-4D75-B421-102AE55BFA86

P5875

Q37272035-37B64A71-DD06-41A1-A571-B7A5F1800441

P698

Q37272035-3E951836-8951-45A9-A6E8-FD1BD6701481

P932

Q37272035-5897758E-FA2F-48FD-9686-6747D40160FE

P356

BLOOD-2013-04-496893

P1433

P1476

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

@en

P2093

Abigail M Lee

http://www.w3.org/2001/XMLSchema#string

Alexander Kohlmann

http://www.w3.org/2001/XMLSchema#string

Andreas Rosenwald

http://www.w3.org/2001/XMLSchema#string

Andrew Clear

http://www.w3.org/2001/XMLSchema#string

András Matolcsy

http://www.w3.org/2001/XMLSchema#string

Ciarán O'Riain

http://www.w3.org/2001/XMLSchema#string

George Wright

http://www.w3.org/2001/XMLSchema#string

German Ott

http://www.w3.org/2001/XMLSchema#string

Hajnalka Rajnai

http://www.w3.org/2001/XMLSchema#string

Jacek Marzec

http://www.w3.org/2001/XMLSchema#string

P2860

The Polycomb group protein EZH2 directly controls DNA methylation

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

P304

3165-3168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-04-496893

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Erlend B. Smeland

Olivier Elemento

Jude Fitzgibbon

Torsten Haferlach

P577

2013-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256838231

http://www.w3.org/2001/XMLSchema#string

P698

24052547

http://www.w3.org/2001/XMLSchema#string

P932

3814734

http://www.w3.org/2001/XMLSchema#string